Progenika Plans to Commercialize Array-Based Tests for Blood Typing, FH This Year | GenomeWeb

Array-based test maker Progenika this year plans to commercialize assays for blood typing and familial hypercholesterolemia in the US and Europe, and may submit one or both tests to the US Food and Drug Administration for future clearance, according to a company official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.